article thumbnail

Raman spectroscopy market expected to value $875m by 2028

European Pharmaceutical Review

million by 2028, with a CAGR of 7.3 percent from 2023 to 2028. Between 2023 to 2028, the research suggested that a greater focus on drug development, growing requirement for spectroscopy via cloud-based platforms, alongside the industry’s need for precise and effective analytical methods, will drive the market.

article thumbnail

US companies drive 2023 drug launches positioned for blockbuster success by 2028

Pharmaceutical Technology

According to GlobalData’s Looking Ahead to 2023 – the Future of Pharma report, five drugs set for approval in 2023 are projected to attain blockbuster status or near-blockbuster status by 2028 with US company dominance. These drugs are set to make a combined $4.34bn in sales in 2028.

Sales 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Alzheimer’s drug Leqembi set to generate $12.9bn in sales by 2028

Pharmaceutical Technology

The breakthrough drug is predicted to be a blockbuster, generating total forecast sales of $12.9bn between 2023 and 2028. Leqembi is forecast to generate total sales of $12.9bn worldwide between 2023 and 2028. The forecast total sales of $12.9bn by 2028 underscores the significant impact Leqembi is expected to have on the market.

Sales 59
article thumbnail

Alzheimer’s drug Leqembi set to generate $12.9bn in sales by 2028

Pharmaceutical Technology

The breakthrough drug is predicted to be a blockbuster, generating total forecast sales of $12.9bn between 2023 and 2028. Leqembi is forecast to generate total sales of $12.9bn worldwide between 2023 and 2028. The forecast total sales of $12.9bn by 2028 underscores the significant impact Leqembi is expected to have on the market.

Sales 52
article thumbnail

Report: Oncology, Immunology Projected to Lead Global Spending From 2024 to 2028

Pharmacy Times

The IQVIA Global Use of Medicines report for 2024 predicts that loss of brand exclusivity will negatively impact global market growth.

Leads 58
article thumbnail

Germany largest revenue contributor in Europe’s LIMS market

European Pharmaceutical Review

million by 2028. percent between 2022-2028, the research found. Based on the research, the US LIMS market is predicted to value $1 billion by 2028. This is “leading to the adoption of cloud-based lab automation solutions”, the report added. The market is growing at a CAGR of 10.16

article thumbnail

Acute lymphocytic leukaemia leads in cell therapy clinical development

Pharmaceutical Technology

The leading marketed CAR-T cell products, Gilead’s Yescarta (axicabtagene ciloleucel) and Novartis’ Kymriah (tisagenlecleucel), achieved $695m and $587m in sales respectively last year, demonstrating the high potential for sales of successful new cell therapies.

Leads 52